Approval Year
| Substance Class |
Structurally Diverse
Created
by
admin
on
Edited
Fri Dec 15 18:48:46 GMT 2023
by
admin
on
Fri Dec 15 18:48:46 GMT 2023
|
| Source Materials Class | ORGANISM |
| Source Materials Type | BACTERIUM |
| Source Materials State | LIVE |
| Organism Family | Mycobacteriaceae |
| Organism Genus | Mycobacterium |
| Organism Species | tuberculosis |
| Author | (ZOPF, 1883) LEHMANN AND NEUMANN, 1896 |
| Part | WHOLE |
| Record UNII |
R0EM8D5HFD
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
R0EM8D5HFD
Created by
admin on Fri Dec 15 18:48:46 GMT 2023 , Edited by admin on Fri Dec 15 18:48:46 GMT 2023
|
PRIMARY | |||
|
1492936
Created by
admin on Fri Dec 15 18:48:46 GMT 2023 , Edited by admin on Fri Dec 15 18:48:46 GMT 2023
|
PRIMARY | RxNorm | ||
|
1773
Created by
admin on Fri Dec 15 18:48:46 GMT 2023 , Edited by admin on Fri Dec 15 18:48:46 GMT 2023
|
PRIMARY | |||
|
R0EM8D5HFD
Created by
admin on Fri Dec 15 18:48:46 GMT 2023 , Edited by admin on Fri Dec 15 18:48:46 GMT 2023
|
PRIMARY | |||
|
963806
Created by
admin on Fri Dec 15 18:48:46 GMT 2023 , Edited by admin on Fri Dec 15 18:48:46 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
INHIBITOR->TARGET ORGANISM |
Despite its broad structural similarity to EMB retained good activity against EMB-resistant Mtb strains (MIC 2.4 μM, cf. 1.2 μMNagainst H37Rv).
MIC
|
||
|
VACCINE ANTIGEN->TARGET ORGANISM |
|
||
|
|
INHIBITOR->TARGET ORGANISM |
|
||
|
VACCINE ANTIGEN->TARGET ORGANISM | |||
|
|
INHIBITOR->TARGET ORGANISM |
|
||
|
|
INHIBITOR->TARGET ORGANISM |
MIC
|
||
|
VACCINE ANTIGEN->TARGET ORGANISM | |||
|
INHIBITOR->TARGET ORGANISM | |||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
VACCINE ANTIGEN->TARGET ORGANISM | |||
|
VACCINE ANTIGEN->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM | |||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
MIC90
|
||
|
VACCINE ANTIGEN->TARGET ORGANISM | |||
|
VACCINE ANTIGEN->TARGET ORGANISM | |||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM | |||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM | |||
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR->TARGET ORGANISM |
Demonstrates efficacy in a rodent model of tuberculosis.
MIC
|
||
|
VACCINE ANTIGEN->TARGET ORGANISM | |||
|
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR -> TARGET |
|
||
|
INHIBITOR->TARGET ORGANISM | |||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
Intracellular M. Tb
IC50
|
||
|
INFRASPECIFIC -> PARENT ORGANISM |
|
||
|
VACCINE ANTIGEN->TARGET ORGANISM | |||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
A broad spectrum antibiotic.In
phase I clinical trials, found to have better safety (milder side effects) than LZD due to its more rapid
clearance,88 although final results from a phase IIa EBA
study may suggest lower efficacy than both LZD and sutezolid.
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
40 strains
MIC90
|
||
|
INFRASPECIFIC -> PARENT ORGANISM |
|
||
|
VACCINE ANTIGEN->TARGET ORGANISM |
|
||
|
INFRASPECIFIC -> PARENT ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM | |||
|
VACCINE ANTIGEN->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
VACCINE ANTIGEN->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM |
MIC
|
||
|
INHIBITOR->TARGET ORGANISM |
|
||
|
INHIBITOR->TARGET ORGANISM | |||
|
VACCINE ANTIGEN->TARGET ORGANISM |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|